Cancer in Norway

IARC estimates 39,345 new cancer cases and 12,472 cancer deaths in Norway in 2024; the commonest new cancers are prostate, colorectum and breast. This page is assembled automatically from OnCo's data: 238 trials with a site there, 5 institutions, 5 companies, 5 people and 1 programme or law, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

39,345

all cancers

Deaths

12,472

all cancers

Incidence rate

334.6

per 100,000, age-standardised

Mortality rate

86.4

per 100,000, age-standardised

Cumulative risk

31.9%

of a cancer by age 74

Population

5,576,665

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	5,671	94.1	Prostate cancer
Colorectum	5,102	39.7	Colorectal cancer
Breast	4,500	93.6	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	3,626	26.7	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Melanoma of skin	2,858	26.5	Melanoma
Bladder	1,710	12.2	Bladder & urothelial cancer
Non-Hodgkin lymphoma	1,231	10.9	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Pancreas	1,052	7.9	Pancreatic ductal adenocarcinoma
Kidney	976	9.3	Renal cell carcinoma
Leukaemia	862	8.9	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	2,462	17.3	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	1,998	13.1	Colorectal cancer
Pancreas	969	6.9	Pancreatic ductal adenocarcinoma
Prostate	871	9.8	Prostate cancer
Breast	664	10.4	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Leukaemia	415	3.0	Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia
Non-Hodgkin lymphoma	398	2.5	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Bladder	389	2.2	Bladder & urothelial cancer
Brain, central nervous system	387	4.1	Glioma & glioblastoma
Melanoma of skin	338	2.7	Melanoma

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Norway”, in Northern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

238 trials in OnCo · 82 recruiting overall

238 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014) NCT07209111	Phase 2	Recruiting	Merck Sharp & Dohme LLC	72	2026-10-07
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581	Phase 3	Recruiting	Eli Lilly and Company	416	2026-10-07
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	58	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598	Phase 3	Recruiting	Eli Lilly and Company	366	2026-10-07
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	50	2026-10-07
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700	Phase 3	Recruiting	Merck Sharp & Dohme LLC	326	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680	Phase 2	Recruiting	Bristol-Myers Squibb	58	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL NCT04924075	Phase 2	Recruiting	Merck Sharp & Dohme LLC	84	2026-10-06
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Phase 3	Recruiting	Merck Sharp & Dohme LLC	314	2026-10-06
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma NCT06697301	Phase 2/3	Recruiting	Eikon Therapeutics	127	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer NCT07166094	Phase 3	Recruiting	Genmab	177	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re NCT07225270	Phase 3	Recruiting	Genmab	34	2026-10-06
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy NCT07218926	Phase 3	Recruiting	GlaxoSmithKline	156	2026-10-05
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) NCT07585266	Phase 3	Recruiting	GlaxoSmithKline	72	2026-10-05
A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F) NCT07405151	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	32	2026-10-02
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) NCT06796907	Phase 1/2	Recruiting	GlaxoSmithKline	82	2026-10-02
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	49	2026-10-02
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors NCT06172478	Phase 2	Recruiting	Daiichi Sankyo	94	2026-10-01
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P NCT07361510	Phase 3	Recruiting	Bristol-Myers Squibb	284	2026-09-30
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) NCT06079671	Phase 3	Recruiting	AstraZeneca	205	2026-09-30
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Rela NCT07391657	Phase 3	Recruiting	AstraZeneca	143	2026-09-29
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations NCT06581432	Phase 2	Recruiting	Boehringer Ingelheim	92	2026-09-29
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy NCT07544654	Phase 3	Recruiting	Boehringer Ingelheim	167	2026-09-29

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Norway, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Norway is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

5 institutions

Akershus University Hospital Barnekreftforeningen Haukeland University Hospital Norwegian Cancer Society Oslo University Hospital, The Norwegian Radium Hospital

5 companies

NaDeNo Nanoscience Nykode Therapeutics Oncosyne Photocure Zelluna

5 people

People whose main affiliation in OnCo is an institution or company in Norway.

Bjørn Atle Bjørnbeth Kjetil Taskén Michael Bretthauer Oddbjorn Straume Øystein Mæland

Screening, vaccination and law

Term

Cervical cancer screening programme in Norway

Norway runs a national cervical cancer screening programme started in 1995, offering cytology (Pap test) and HPV test, as recorded by IARC's CanScreen5 survey (2020).

Approvals

OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Norway is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.

From the country research ranking

Research funders: Norwegian Cancer Society; Research Council of Norway.
Named in the ranking: Cancer Registry of Norway and Oslo University Hospital.

From the country ranking's hand-curated row; follow its source before relying on a figure.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Norway's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Norway, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines regulator, its approval routes and its decisions.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Norway's own sources, beyond the programme records above.

A deep dive for Norway is ranked 53 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today; Norway fact sheet.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/no.json; every country: /api/v1/countries.json.